153 related articles for article (PubMed ID: 37526174)
1. Impact of treatment on blood-brain barrier impairment in Wilson's disease.
Misztal M; Członkowska A; Cudna A; Palejko A; Litwin T; Piechal A; Kurkowska-Jastrzębska I
Neurol Neurochir Pol; 2023; 57(4):379-386. PubMed ID: 37526174
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of clinical rating scales in Wilson's disease.
Volpert HM; Pfeiffenberger J; Gröner JB; Stremmel W; Gotthardt DN; Schäfer M; Weiss KH; Weiler M
BMC Neurol; 2017 Jul; 17(1):140. PubMed ID: 28732478
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson's disease.
Ziemssen T; Smolinski L; Członkowska A; Akgun K; Antos A; Bembenek J; Kurkowska-Jastrzębska I; Przybyłkowski A; Skowrońska M; Redzia-Ogrodnik B; Litwin T
Acta Neurol Belg; 2023 Jun; 123(3):917-925. PubMed ID: 36098934
[TBL] [Abstract][Full Text] [Related]
4. Optical coherence tomography as a marker of neurodegeneration in patients with Wilson's disease.
Langwińska-Wośko E; Litwin T; Dzieżyc K; Karlinski M; Członkowska A
Acta Neurol Belg; 2017 Dec; 117(4):867-871. PubMed ID: 28488258
[TBL] [Abstract][Full Text] [Related]
5. Brain magnetic resonance imaging and severity of neurological disease in Wilson's disease - the neuroradiological correlations.
Rędzia-Ogrodnik B; Członkowska A; Bembenek J; Antos A; Kurkowska-Jastrzębska I; Skowrońska M; Smoliński Ł; Litwin T
Neurol Sci; 2022 Jul; 43(7):4405-4412. PubMed ID: 35275318
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale.
Członkowska A; Litwin T; Dzieżyc K; Karliński M; Bring J; Bjartmar C
BMC Neurol; 2018 Apr; 18(1):34. PubMed ID: 29621974
[TBL] [Abstract][Full Text] [Related]
7. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
8. Early neurological worsening in patients with Wilson's disease.
Litwin T; Dzieżyc K; Karliński M; Chabik G; Czepiel W; Członkowska A
J Neurol Sci; 2015 Aug; 355(1-2):162-7. PubMed ID: 26071888
[TBL] [Abstract][Full Text] [Related]
9. Plasma neurofilament light chain as a biomarker in Wilson's disease.
Yang J; Huang Z; Yang H; Luo Y; You H; Chen D; Pei Z; Li X
Parkinsonism Relat Disord; 2022 Feb; 95():5-10. PubMed ID: 34942565
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum brain natriuretic peptide and matrix metalloproteinases 2 and 9 in Wilson's disease.
Cheng N; Wang H; Dong J; Pan S; Wang X; Han Y; Han Y; Yang R
Metab Brain Dis; 2015 Aug; 30(4):1087-91. PubMed ID: 26077744
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of neurological Wilson's disease with corpus callosum abnormalities.
Zhou ZH; Wu YF; Cao J; Hu JY; Han YZ; Hong MF; Wang GQ; Liu SH; Wang XM
BMC Neurol; 2019 May; 19(1):85. PubMed ID: 31053106
[TBL] [Abstract][Full Text] [Related]
12. Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China.
Li LY; Yang WM; Chen HZ; Wu YH; Fang X; Zhang J; Wang Z; Han YS; Wang Y
PLoS One; 2015; 10(4):e0124569. PubMed ID: 25910248
[TBL] [Abstract][Full Text] [Related]
13. Liver Transplantation in Wilson's Disease with Neurological Impairment: Evaluation in 4 Patients.
Laurencin C; Brunet AS; Dumortier J; Lion-Francois L; Thobois S; Mabrut JY; Dubois R; Woimant F; Poujois A; Guillaud O; Lachaux A; Broussolle E
Eur Neurol; 2017; 77(1-2):5-15. PubMed ID: 27866189
[TBL] [Abstract][Full Text] [Related]
14. Brain volume is related to neurological impairment and to copper overload in Wilson's disease.
Smolinski L; Litwin T; Redzia-Ogrodnik B; Dziezyc K; Kurkowska-Jastrzebska I; Czlonkowska A
Neurol Sci; 2019 Oct; 40(10):2089-2095. PubMed ID: 31147855
[TBL] [Abstract][Full Text] [Related]
15. Paramagnetic Metal Accumulation in the Deep Gray Matter Nuclei Is Associated With Neurodegeneration in Wilson's Disease.
Yuan XZ; Li GY; Chen JL; Li JQ; Wang XP
Front Neurosci; 2020; 14():573633. PubMed ID: 33041766
[TBL] [Abstract][Full Text] [Related]
16. [Mild cognitive impairment and depressive symptoms in patients with Wilson's disease under long-term therapy].
Günther P; Hermann W
Fortschr Neurol Psychiatr; 2012 Mar; 80(3):149-53. PubMed ID: 22407412
[TBL] [Abstract][Full Text] [Related]
17. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease.
Stuerenburg HJ
J Neural Transm (Vienna); 2000; 107(3):321-9. PubMed ID: 10821440
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease.
Leinweber B; Möller JC; Scherag A; Reuner U; Günther P; Lang CJ; Schmidt HH; Schrader C; Bandmann O; Czlonkowska A; Oertel WH; Hefter H
Mov Disord; 2008 Jan; 23(1):54-62. PubMed ID: 17960799
[TBL] [Abstract][Full Text] [Related]
19. Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series.
De Fabregues O; Viñas J; Palasí A; Quintana M; Cardona I; Auger C; Vargas V
Brain Behav; 2020 May; 10(5):e01596. PubMed ID: 32202078
[TBL] [Abstract][Full Text] [Related]
20. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
